

Focused Panel

Designed specifically for your advanced NSCLC patients



Alterations associated with NSCLC which are currently well-established

ALK	BRAF	EGFR	ERBB2 (HER2)	RET
KRAS	MET	ROS1	STK11	NTRK1

Alterations associated with:

- ✓ FDA-approved targeted therapies
- ✓ Indicators for resistance to therapy
- ✓ Inclusion or exclusion criteria for clinical trials
- ✓ An FDA approved drug for a different tumor type

AKT1	CCND1	CDKN2A	CTNNB1	ESR1	FGFR1	FGFR2
FGFR3	GATA3	GNA11	GNAQ	GNAS	HRAS	IDH1
IDH2	KIT	MAP2K1	MYC	NFE2L2	NRAS	NTRK3
PDGFRA	PIK3CA	PP2R1A	PTEN	TP53	U2AF1	

Gene key

SNVs + Indels -
Hotspot Regions

Fusions + SNVs + Indels

CNVs + SNVs + Indels

SNVs + Indels -
Exon Coverage 70% for
PTEN, 88-100% for TP53,
STK11 and CDKN2A

Fusions

CNVs only

FDA-approved targeted therapies in NSCLC

Genomic driver	Available targeted therapies
ALK rearrangement	alectinib (ALECENSA®), brigatinib (ALUNBRIG®), ceritinib (ZYKADIA®), crizotinib (XALKORI®), lorlatinib (LORBRENA®)
BRAF V600E mutation	dabrafenib (TAFINLAR®) + trametinib (MEKINIST®)
EGFR mutation	afatinib (GILOTRIF®), amivantamab-vmjw (RYBREVA™), dacomitinib (VIZIMPRO®), erlotinib (TARCEVA®), gefitinib (IRESSA®), mobocertinib (EXKIVITY™), osimertinib (TAGRISSO®), ramucirumab (CYRAMZA®)
KRAS G12C mutation	sotorasib (LUMAKRAS™)
MET amplification/mutation	capmatinib (TABRECTA™), tepotinib (TEPMETKO®)
NTRK rearrangement	entrectinib (ROZLYTREK™), larotrectinib (VITRAKVI®)
RET rearrangement	pralsetinib (GAVRETO™), selpercatinib (RETEVMO™)
ROS1 rearrangement	crizotinib (XALKORI®), entrectinib (ROZLYTREK™)

Order now to guide your decisions for your advanced NSCLC Patients

Please complete your own review for each patient. Clinical guidelines may support additional therapies, therapeutic combinations, and new FDA approvals.

USA Toll Free
866.776.5907

 neogenomics.com

 @NeoGenomics

 client.services@neogenomics.com

 NeoGenomics Laboratories

© 2021 NeoGenomics Laboratories, Inc. All Rights Reserved. InVisionFirst is a UK, EU and US registered trade mark of Inivata Limited. All other trademarks are the property of their respective owners. CORP-MRKT-0072 Rev. 100421

